The publication of this infographic was funded by Boehringer Ingelheim. This content is intended for US Healthcare Professionals.
Zongertinib is a tyrosine kinase inhibitor (TKI) that selectively inhibits HER2 (ERBB2). This orally administered, targeted therapy was approved as HERNEXEOS® (zongertinib tablets) under the FDA’s Accelerated Approval Program, after securing Priority Review as well as Breakthrough Therapy and Fast Track Designations. Please see full Prescribing Information for HERNEXEOS.
In HER2 (ERBB2)-mutant NSCLC, brain metastases present a significant unmet need. Read this infographic to explore the intracranial activity of zongertinib and its systemic efficacy and safety in patients with and without brain metastases at baseline.
Uncover:
- How common are brain metastases in HER2-mutant NSCLC?
- Does zongertinib provide intracranial response without prior brain radiotherapy?
- How consistent is systemic activity in patients with and without brain metastases?
- What does the safety profile look like in patients with stable, asymptomatic brain metastases?
